Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07633613 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Study acronym: CPI
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Dec 2028 → May 2029
See other at-risk trials from Centre Antoine Lacassagne

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 2026 to Oct 2026
    • Primary and study completion pushed from Dec 2028 to May 2029
    • Eligibility criteria expanded, about 3 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) not amenable to curative local treatment.
Trial Details
NCT Number NCT07633613
Lead Sponsor Centre Antoine Lacassagne
Conditions
(from sponsor)		 Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Related terms Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov